Osteal Therapeutics is a privately-held, clinical-stage pharmaceutical company developing novel musculoskeletal therapeutics to treat orthopedic infections and their consequences.

Johnson & Johnson Robotics and Digital Solutions

MedVest Fund II

Medvest Capital

Johnson & Johnson Development Corporation

HM Capital

Huimei Capital

Prism Venture Management

Asteroid Partners

Gideon Strategic Partners

GOS Capital

Osteal Therapeutics

Osteal Therapeutics’ VT-X7 Receives FDA’s Breakthrough Therapy Designation for the treatment of periprosthetic joint infection of the hip and knee and completes enrollment of the pivotal APEX-2 trial.
https://bit.ly/3Gqtl1n


Osteal Therapeutics is proud to be named as a 2023 Rising Star by Bio North Texas! 

Osteal Therapeutics Closes Over Subscribed Series C Financing. We're able to focus on lifting the burden of periprosthetic joint infection because of the tremendous support from our existing and new investors. Their enthusiasm is validating and energizing. 

https://bit.ly/45ZVF5A

Our President & CEO, David Thompson, is presenting at #LSIEurope23 in Barcelona this week. 

If you're attending, make sure you listen to his talk about the amazing journey Osteal Therapeutics is on to lift the burden of periprosthetic joint infection. 

#LSIAlumni #medtech

Osteal Therapeutics is a biotechnology company focused on developing advanced regenerative medicine therapies to treat a variety of conditions, particularly those related to bone and cartilage. Their approach involves the use of stem cell-based therapies to repair and regenerate damaged tissues.

COM:OSTEALTX

Osteal Therapeutics

Filings Not Available